EIA’s research, conducted over the past two years, reveals the continued online availability of at least 88 traditional Chinese medicine (TCM) products stated to contain leopard, pangolin and, in a few cases, tiger and rhino, manufactured by 72 Chinese companies which have been licensed by the National Medical Products Administration of China.
This comprehensive toolkit brings together in one place a range of measures and resources that governments of tiger range countries can use to counter trafficking of tigers, their parts and derivatives – including from farmed tigers.
Unfettered growth of TCM poses a serious threat to biodiversity in Africa, all in the name of short-term profit. Any utilisation of threatened species in TCM could stimulate further demand, incentivise wildlife crime and ultimately lead to overexploitation.
The world’s eight pangolin species are experiencing catastrophic levels of poaching and trafficking to feed demand for their scales, meat and other body parts. In 2016, the global community agreed to make the international commercial trade in pangolins and their parts and derivatives illegal.
EIA research reveals that at least twenty-four Chinese pharmaceutical companies have been listing leopard bones as an ingredient in their traditional medicines, although there are fewer than 450 wild leopards left in that country.